Valuation: Cogent Biosciences, Inc.

Market Cap 512.38Cr 456.73Cr 423.09Cr 384.69Cr 721.85Cr 49TCr 733.72Cr 5.07TCr 2TCr 25TCr 1.92TCr 1.88TCr 81TCr P/E 2026 *
-13.1x
P/E 2027 * -26.8x
Enterprise Value 499.41Cr 445.17Cr 412.38Cr 374.95Cr 703.59Cr 47TCr 715.16Cr 4.95TCr 1.95TCr 25TCr 1.87TCr 1.83TCr 79TCr EV / Sales 2026 *
834x
EV / Sales 2027 * 17.5x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.66%
1 week+0.77%
Current month-6.28%
1 month-6.22%
3 months-21.64%
6 months-18.89%
Current year-15.51%
1 week 27.74
Extreme 27.735
30.23
1 month 27.74
Extreme 27.735
32.85
Current year 27.74
Extreme 27.735
43.39
1 year 13.78
Extreme 13.78
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

759 0.0004%
27/08/26 Exercice

Director

1,36,530 0.0787%
01/07/26 Free

Director

627 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%+0.77%+85.02%+233.82% 512.38Cr
+1.52%-7.16%+51.66%+67.41% 6.5TCr
+1.52%+7.17%+10.77%+77.89% 5.12TCr
+0.30%+0.19%+2.53%+56.14% 5.12TCr
-0.38%+1.40%+25.39%+42.37% 4.39TCr
+0.30%+5.64%+16.19%+133.30% 4.2TCr
+2.35%-6.08%+237.25%+528.10% 3.81TCr
+2.16%+10.36%+18.92%+59.70% 3.32TCr
-0.90%-10.49%+37.09%+1.80% 2.52TCr
+1.60%+3.97%+21.34%+22.33% 2.25TCr
Average +0.98%-0.35%+50.61%+122.29% 3.77TCr
Weighted average by Cap. +0.93%-0.03%+45.99%+112.78%

Financials

2026 *2027 *
Net sales 59.89L 53.38L 49.45L 44.96L 84.37L 57Cr 85.76L 5.93Cr 2.33Cr 30Cr 2.25Cr 2.2Cr 95Cr 28Cr 25Cr 23Cr 21Cr 40Cr 2.69TCr 41Cr 280.99Cr 110.49Cr 1.41TCr 106.44Cr 104.22Cr 4.49TCr
Net income -40Cr -36Cr -33Cr -30Cr -56Cr -3.78TCr -57Cr -395.12Cr -155.37Cr -1.98TCr -149.68Cr -146.55Cr -6.32TCr -21Cr -19Cr -18Cr -16Cr -30Cr -2.02TCr -30Cr -210.87Cr -83Cr -1.06TCr -80Cr -78Cr -3.37TCr
Net Debt -13Cr -12Cr -11Cr -9.73Cr -18Cr -1.23TCr -19Cr -128.41Cr -50Cr -642.45Cr -49Cr -48Cr -2.05TCr -16Cr -14Cr -13Cr -12Cr -22Cr -1.5TCr -23Cr -156.57Cr -62Cr -783.33Cr -59Cr -58Cr -2.5TCr
Projected Income Statement - Annual - Cogent Biosciences, Inc.
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
20/26/20 $30.01 +1.66% 25,41,173
16/26/16 $29.52 +0.03% 27,83,048
15/26/15 $29.51 +4.83% 30,39,765
14/26/14 $28.15 +0.21% 22,95,507
13/26/13 $28.09 -5.67% 29,95,450
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Cogent Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
29.52USD
Average target price
55.82USD
Spread / Average Target
+89.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cogent Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. COGT Stock